References

Alonso, P.L., J. Sacarlal, J.J. Aponte, A. Leach and E. Macete et al., 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomized controlled trial. Lancet, 366: 2012-2018.
CrossRef  |  

Asante, K.P., S. Abdulla, S. Agnandji, J. Lyimo and J. Vekemans et al., 2011. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded programme-on-immunisation vaccines: 19 month follow-up of a randomized, open-label phase 2 trial. Lancet Infect. Dis., 10.1016/S1473-3099(11)70100-1

Ballou, W.R., 2009. The development of RTS, S malaria vaccine candidate: Challenges and lessons. Parasite Immunol., 31: 492-500.
PubMed  |  

Ballou, W.R., J.A. Sherwood, F.A. Neva, D.M. Gordon and R.A. Wirtz et al., 1987. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet, 329: 1277-1281.
CrossRef  |  

Bouharoun-Taoun, H. and P. Druilhe, 1992. Plasmodium falciparum malaria: Evidence for isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immunity, 60: 1473-1481.
Direct Link  |  

Chougnet, C., J. Lepers, P. Astagneau, M. Rason, J. Savel and P. Deloron, 1991. Lymphoproliferative responses to synthetic peptides from merozoite ring-infected erythrocyte surface antigen and circumsporozoite protein: A longitudinal study during falciparum malaria episode. Am. J. Trop. Med. Hyg., 45: 560-566.
PubMed  |  

Cohen, J., V. Nussenzweig, R. Nussenzweig, J. Vekemans and A. Leach, 2010. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccines, 6: 90-96.
PubMed  |  

Doolan, D.L. and S.L. Hoffman, 2001. DNA-based vaccines against malaria: Status and promise of the multi-stage malaria DNA vaccine operation. Int. J. Parasitol., 31: 753-762.
CrossRef  |  

Dubois, B., P. Deloron, P. Astagneau, C. Chougnet and J.P. Lepers, 1993. Isotypic analysis of Plasmodium falciparum-specific antibodies and their relation to protection in Madagascar. Infect. Immunity, 60: 4498-4500.
Direct Link  |  

Good, M.F. and D.L. Doolan, 1999. Immune effector mechanisms in malaria. Curr. Opin. Immunol., 11: 412-419.
CrossRef  |  

Groux, H. and J. Gysin, 1990. Opsonisation as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: Functional role of IgG subclasses. Res. Immunol., 141: 532-542.
PubMed  |  

Gruner, A.C., M. Mauduit, R. Tewari, J.F. Romero and N. Depinay et al., 2007. Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PLoS One, Vol. 2,

Hoffman, S.L., C.N. Oster, C.V. Plowe, G.R. Woollett and J.C. Beier et al., 1987. Naturally acquired antibodies to sporozoites do not protect against malaria: Vaccine development implications. Science, 237: 639-642.
CrossRef  |  

John, C.C., J.S. Zickafoose, P.O. Sumba, C.L. King and J.W. Kazura, 2003. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect. Immunity, 71: 4320-4325.
PubMed  |  

Khusmith, S. and P. Druilhe, 1983. Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect. Immunity, 41: 219-223.
PubMed  |  

Nwagwu, M., C.A. Anumudu, O. Sodeinde, C.A. Ologunde and T.U. Obi et al., 1998. Identification of a subpopulation of immune Nigeria adult volunteers by antibodies to the circumsporozoite protein of Plasmodium falciparum. Am. J. Trop. Med. Hyg., 58: 684-692.
PubMed  |  

Olotu, A., J. Lusingu, A. Leach, M. Lievens and J. Vekemans et al., 2011. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: A randomised controlled trial. Lancet Infect. Dis., 11: 102-109.
PubMed  |  

Salako, L.A., F.O. Ajayi, A. Sowunmi and O. Walker, 1990. Malaria in Nigeria a revisit. Ann. Trop. Med. Parasitol., 84: 435-445.
PubMed  |  

Singh, J.P.N., S. Verma, P.R. Bhattacharya, N. Srivastava, A.P. Dash and S. Biswas, 2009. Plasmodium falciparum circumsporozoite protein: Epidemiological variations among field isolates prevalent in India. Trop. Med. Int. Health, 14: 957-966.
PubMed  |  

Sutherland, C., 2007. A challenge for the development of malaria vaccines: Polymorphic target antigens. PLoS Med., Vol. 4, 10.1371/journal.pmed.0040116

WHO, 2010. World malaria report 2010. World Health Organization Regional Office for the Western Pacific, Geneva, Switzerland, pp: 1-204.

Wirtz, R.A., J.F. Duncan, E.K. Njelesani, I. Schneider and A.E. Brown et al., 1989. ELISA method for detecting Plasmodium falciparum circumsporozoite antibody. Bull. World Health Org., 67: 535-542.
PubMed  |  

Yazdani, S.S., P. Mukherjee, V.S. Chauhan and C.E. Chitnis, 2006. Immune responses to asexual blood-stages of malaria parasites. Curr. Mol. Med., 6: 187-203.
PubMed  |  

Young, J.F., W.T. Hockmeyer, M. Gross, W.R. Ballou and R.A. Wirtz et al., 1985. Expression of Plasmodium falciparum circumsporozoite protein in Escherichia coli for potential use in a human malaria vaccine. Science, 228: 958-962.
PubMed  |  

Yount, W.J., R. Hong, M. Seligmann, R. Good and H.G. Kunkel, 1970. Imbalances of gamma globulin subgroups and gene defects in patients with primary hypogammaglobulinaemia. J. Clin. Invest., 49: 1957-1966.
CrossRef  |